Results 31 to 40 of about 757 (146)

Evaluating the effectiveness and safety of Azvudine for hospitalised patients with COVID-19 and hypertension: a multicenter retrospective cohort study [PDF]

Scientific Reports
Hypertension is widely acknowledged as a major risk factor for disease severity and death in patients with coronavirus disease 2019 (COVID-19). Azvudine is recommended for COVID-19 patients in China.
Yu Chen, Huan Li, Yichen Ma, Ling Wang, Guowu Qian, Silin Li, Hong Luo, Shixi Zhang, Guangming Li, Donghua Zhang, Guotao Li, Yun Zheng, Qin Bai, Haiyu Wang, Zhigang Ren   +14 more
doaj   +2 more sources

Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort studyResearch in context

EClinicalMedicine, 2023
Summary: Background: As the COVID-19 pandemic continues to spread, the number of associated deaths continues to increase, especially among those with pre-existing conditions.
Yuming Sun, Liping Jin, Yating Dian, Minxue Shen, Furong Zeng, Xiang Chen, Guangtong Deng   +6 more
doaj   +2 more sources

Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study

Infection and Drug Resistance, 2023
Xiang Zhao,1 Yuan Cheng,1 Meng Zhang,1 Bianba Qianda,2 Baima Zhouma,3 Bianba Yangzhen,3 Yao Zheng,4 Shuo Zhang,5 Huiying Zhao6 1Department of Respiratory and Critical Care Medicine, Peking University First Hospital, Beijing, People’s Republic of China ...
Zhao X, Cheng Y, Zhang M, Qianda B, Zhouma B, Yangzhen B, Zheng Y, Zhang S, Zhao H   +8 more
doaj   +1 more source

Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study

Infectious Diseases and Therapy, 2023
Introduction Azvudine and nirmatrelvir-ritonavir are more extensively used to treat COVID-19 in China due to their earlier approval by the National Medical Products Administration.
Qinqin Zhao, Bei Zheng, Bing Han, Pinpin Feng, Zhongni Xia, Hong Jiang, Yin Ying, Jun Zhu, Cheng Fei, Junlei Xiang, Lingli Shen, Qiliang Luo, Yinhuan Wu, Ayiguzhali Wusiman, Chuanwei Xin, Meiling Zhang, Gonghua Li, Xiang Li   +17 more
doaj   +2 more sources

Effectiveness of azvudine versus nirmatrelvir/ritonavir for hospitalized patients with SARS-CoV-2 infection and pre-existing liver diseases [PDF]

Virology Journal
Background Azvudine and nirmatrelvir/ritonavir are recommended as priority treatments for SARS-CoV-2 infection in China, but their effectiveness and safety in patients with pre-existing chronic liver diseases remains unknown.
Guanyue Su, Feng Gao, Mengzhao Yang, Ling Wang, Lili Liang, Silin Li, Guangming Li, Na Han, Guotao Li, Guowu Qian, Shixi Zhang, Hong Luo, Donghua Zhang, Hongxia Liang, Zhigang Ren   +14 more
doaj   +2 more sources

Azvudine for the Treatment of COVID-19 in Pre-Existing Cardiovascular Diseases: A Single-Center, Real-World Experience

Advanced Science
COVID‐19 can lead to adverse outcomes in patients with pre‐existing diseases. Azvudine has been approved for treating COVID‐19 in China, but the real‐world data is limited. It is aimed to investigate the efficacy of Azvudine in patients with COVID‐19 and
Hong-Da Zhang, Liu Wu
exaly   +2 more sources

Azvudine for the treatment of cancer patients with COVID-19: a multicenter, real-world, retrospective, cohort study [PDF]

BMC Cancer
Background Cancer patients are at an elevated risk for SARS-CoV-2 infection and require vigilant monitoring. The efficacy and safety of Azvudine in treating COVID-19 among this vulnerable group remain under-researched. Methods We conducted a multicenter,
Lei Li, Wenjie Liu, Ling Wang, Mengzhao Yang, Juan Wang, Guotao Li, Guowu Qian, Shixi Zhang, Donghai Liu, Hong Luo, Silin Li, Donghua Zhang, Zujiang Yu, Zhigang Ren   +13 more
doaj   +2 more sources

A multicenter, real-world cohort study: effectiveness and safety of Azvudine in hospitalized COVID-19 patients with pre-existing diabetes [PDF]

Frontiers in Endocrinology
IntroductionDuring the Omicron infection wave, diabetic patients are susceptible to COVID-19, which is linked to a poor prognosis. However, research on the real-world effectiveness and safety of Azvudine, a common medication for COVID-19, is insufficient
Yongjian Zhou, Zecheng Yang, Shixi Zhang, Donghua Zhang, Hong Luo, Di Zhu, Guangming Li, Mengzhao Yang, Xiaobo Hu, Guowu Qian, Guotao Li, Ling Wang, Silin Li, Zujiang Yu, Zhigang Ren   +14 more
doaj   +2 more sources

Effectiveness and safety of azvudine in older adults with mild and moderate COVID-19: a retrospective observational study

BMC Infectious Diseases
Background Azvudine has clinical benefits and acceptable safety against COVID-19, including in patients with comorbidities, but there is a lack of available data for its use in older adult patients.
Zhiguo Zhou, He Zheng, Gui’e Xiao, Xiangping Xie, Jiaxi Rang, Danhong Peng   +5 more
doaj   +2 more sources

Lactate dehydrogenase predicts disease progression outcome in COVID-19 patients treated with Azvudine

Frontiers in Cellular and Infection Microbiology, 2023
BackgroundAzvudine has been approved in China for the treatment of COVID-19 patients. Previous studies have suggested a correlation between high levels of lactate dehydrogenase (LDH) and the severity of COVID-19.
Manyun Mao, Manyun Mao, Manyun Mao, Manyun Mao, Manyun Mao, Yating Dian, Yating Dian, Yating Dian, Yating Dian, Yating Dian, Yuming Sun, Yuming Sun, Yuming Sun, Yuming Sun, Yuming Sun, Wangqing Chen, Wangqing Chen, Wangqing Chen, Wangqing Chen, Wangqing Chen, Wu Zhu, Wu Zhu, Wu Zhu, Wu Zhu, Wu Zhu, Guangtong Deng, Guangtong Deng, Guangtong Deng, Guangtong Deng, Guangtong Deng   +29 more
doaj   +3 more sources